Ikonisys Announces the Results of its Ordinary Annual and Extraordinary General Meeting of September 30, 2024
01 Outubro 2024 - 12:45PM
Business Wire
Adoption of all resolutions submitted to the
vote
Regulatory News:
Ikonisys SA (Euronext Growth Paris: ALIKO), a company
specializing in the early and accurate detection of cancers through
a unique, fully automated solution for medical analysis
laboratories, announces that all the resolutions submitted to the
Ordinary Annual and Extraordinary General Meeting held on September
30, 2024 (the "CGM") have been adopted by the shareholders,
in accordance with the recommendations of the Board of Directors,
and in particular the resolutions relating to the approval of the
parent company and consolidated financial statements for fiscal
year 2023 and the financial delegations to the Board of
Directors.
With a quorum of 57.36%, i.e. 6,189,295 shares to with are
attached 12,101,512 voting rights, the Ikonisys Annual General
Meeting was validly held under the chairmanship of Mr. Mario Mauri,
in his capacity as Chairman of the Company's Board of
Directors.
About Ikonisys Ikonisys SA is a cell-based diagnostics
company based in Paris (France), New Haven (Connecticut, USA) and
Milan (Italy) specialized in the early and accurate detection of
cancer. The company develops, produces and markets the proprietary
Ikoniscope20® platform, a fully-automated solution designed to
deliver accurate and reliable detection and analysis of rare and
very rare cells. Ikonisys has received FDA clearance for several
automated diagnostic applications, which are also marketed in
Europe under CE certification. Through its breakthrough
fluorescence microscopy platform, the company continues to develop
a stream of new tests, including liquid biopsy tests based on
Circulating Tumor Cells (CTC).
For further information, please go to www.Ikonisys.com
View source
version on businesswire.com: https://www.businesswire.com/news/home/20241001979770/en/
Ikonisys Alessandro Mauri CFO investors@ikonisys.com
NewCap Louis-Victor Delouvrier/Aurélie Manavarere
Investor Relations ikonisys@newcap.eu Tel.: +33 (0)1 44 71 94
94
NewCap Nicolas Merigeau Media Relations
Ikonisys@newcap.eu Tel.: +33 (0)1 44 71 94 98
Ikonisys (EU:ALIKO)
Gráfico Histórico do Ativo
De Out 2024 até Nov 2024
Ikonisys (EU:ALIKO)
Gráfico Histórico do Ativo
De Nov 2023 até Nov 2024
